Trial · NCT03552380
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) Via RECIST 1.1 | Phase II, Dose Level 1:Entinostat 5 mg With Nivolumab and Ipilimumab | 20 | 95% Confidence Interval 5.1 to 71.6 | percentage of participants | |
| Objective Response Rate (ORR) Via RECIST 1.1 | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 42.9 | 95% Confidence Interval 9.9 to 81.6 | percentage of participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | Number of patients had at least one adverse event of any grade. | 5 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | Number of patients had at least one adverse event of any grade. | 7 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | Number of patients had at least one grade 3 or greater adverse event. | 5 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | Number of patients had at least one grade 3 or greater adverse event. | 3 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | Number of patients had at least one grade 3 or greater treatment related adverse event | 5 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | Number of patients had at least one grade 3 or greater treatment related adverse event | 2 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | Number of patients having serious adverse event. | 3 | Participants | |
| Number of Participants With Adverse Events | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | Number of patients having serious adverse event. | 3 | Participants | |
| Objective Response Rate Via Immune Related Response Criteria (irRC) | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 20 | 95% Confidence Interval 5.1 to 71.6 | Percentage of participants | |
| Objective Response Rate Via Immune Related Response Criteria (irRC) | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 28.6 | 95% Confidence Interval 3.7 to 71 | Percentage of participants | |
| Progression Free Survival (PFS) Via RECIST 1.1 | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 4.3 | 95% Confidence Interval 1.3 to NA | months | |
| Progression Free Survival (PFS) Via RECIST 1.1 | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 11.7 | 95% Confidence Interval 1.9 to NA | months | |
| Progression Free Survival (PFS) Via irRC | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 4.3 | 95% Confidence Interval 1.3 to NA | months | |
| Progression Free Survival (PFS) Via irRC | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 11.7 | 95% Confidence Interval 5.9 to NA | months | |
| Overall Survival (OS) | Phase II, Dose Level 1: Entinostat 5 mg With Nivolumab and Ipilimumab | 49.9 | 95% Confidence Interval 6.7 to NA | months | |
| Overall Survival (OS) | Phase II, Dose Level 2: Entinostat 3 mg With Nivolumab and Ipilimumab | 36 | 95% Confidence Interval 5.9 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03552380/results